PIK3CB
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
As of the edition of 20 October 2026, PIK3CB (phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, UniProt P42338) has 29 drugs tested at it and 27 companies on the list, 18 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P42338
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Urinary and reproductive; Lungs and airways; Immune system; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 281
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 3 |
| Went quiet | 12 |
| Stopped | 12 |
| Status not established | 1 |
| Total | 29 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Buparlisib | Stopped | Phase 3 | none listed |
| Dactolisib | Went quiet | Phase 3 | none listed |
| Gedatolisib | Marketed | Phase 3 | Ends 2031 |
| Samotolisib | Stopped | Phase 2 | none listed |
| Pictilisib | Went quiet | Phase 2 | none listed |
| Taselisib | Stopped | Phase 3 | none listed |
| Paxalisib | Active | Phase 3 | none listed |
| Pilaralisib | Went quiet | Phase 2 | none listed |
| Apitolisib | Active | Phase 2 | none listed |
| Voxtalisib | Went quiet | Phase 2 | none listed |
| Bimiralisib | Stopped | Phase 2 | none listed |
| GSK-2636771 | Active | Phase 2 | none listed |
12 of 29 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 18 |
| Route B | 1 |
| Engaged | 6 |
| Undetermined | 2 |
| Total on the list | 27 |
The other 24 companies at PIK3CB
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at PIK3CB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.